Kera Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kera Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,706	Closed	-$201K	–	558
2025 Q3	$201K	Sell	3,706 -46	-1%	-$2.63K	0.03%	402
2025 Q2	$206K	Buy	+3,752	New	+$221K	0.04%	325

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Kera Capital Partners's BMRN Position: Q4 2025 in Review

Kera Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 3,706 shares — an estimated $201K sold.

Kera Capital Partners first reported a position in BMRN in Q2 2025 and held it in 2 quarters. The position peaked at $206K in Q2 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Kera Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Kera Capital Partners sold 3,706 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $201K.
Kera Capital Partners first reported a position in BioMarin Pharmaceuticals in Q2 2025 and held it in 2 quarters.
Kera Capital Partners's BioMarin Pharmaceuticals position peaked at $206K in Q2 2025.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Kera Capital Partners's 13F filing for Q4 2025, filed 23 Feb 2026.